These results indicate that in PBMC of patients affected by thyroid cancer, Pep3 treatment can alter the percentages of CD8+ and CD4+ Treg, CD8+ and CD4+ Teff cells, as well as of CD8+ and CD4+ Teff activated cells and favor an anticancer immune response. This evidence concerns the gene VPS18 and thyroid cancer.